Crossmark

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

Crossref DOI link: https://doi.org/10.1245/s10434-016-5286-0

Published Online: 2016-06-24

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Andtbacka, Robert H. I.

Ross, Merrick

Puzanov, Igor

Milhem, Mohammed

Collichio, Frances

Delman, Keith A.

Amatruda, Thomas

Zager, Jonathan S.

Cranmer, Lee

Hsueh, Eddy

Chen, Lisa

Shilkrut, Mark

Kaufman, Howard L.
License Information

License valid from 2016-06-24